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Background
Tuberculosis remains an important cause of death among patients infected with the 
human immunodeficiency virus (HIV). Robust data are lacking with regard to the 
  timing for the initiation of antiretroviral therapy (ART) in relation to the start of 
antituberculosis therapy.
Methods
We tested the hypothesis that the timing of ART initiation would significantly affect 
mortality among adults not previously exposed to antiretroviral drugs who had newly 
diagnosed tuberculosis and CD4+ T-cell counts of 200 per cubic millimeter or lower. 
After beginning the standard, 6-month treatment for tuberculosis, patients were 
randomly assigned to either earlier treatment (2 weeks after beginning tuberculosis 
treatment) or later treatment (8 weeks after) with stavudine, lamivudine, and efavi-
renz. The primary end point was survival.
Results
A total of 661 patients were enrolled and were followed for a median of 25 months. The 
median CD4+ T-cell count was 25 per cubic millimeter, and the median viral load was 
5.64 log10 copies per milliliter. The risk of death was significantly reduced in the group 
that received ART earlier, with 59 deaths among 332 patients (18%), as compared with 
90 deaths among 329 patients (27%) in the later-ART group (hazard ratio, 0.62; 95% 
confidence interval [CI]; 0.44 to 0.86; P = 0.006). The risk of tuberculosis-associated 
immune reconstitution inflammatory syndrome was significantly increased in the 
earlier-ART group (hazard ratio, 2.51; 95% CI, 1.78 to 3.59; P<0.001). Irrespective of the 
study group, the median gain in the CD4+ T-cell count was 114 per cubic millimeter, 
and the viral load was undetectable at week 50 in 96.5% of the patients.
Conclusions
Initiating ART 2 weeks after the start of tuberculosis treatment significantly improved 
survival among HIV-infected adults with CD4+ T-cell counts of 200 per cubic milli-
meter or lower. (Funded by the French National Agency for Research on AIDS and 
Viral Hepatitis and the National Institutes of Health; CAMELIA ClinicalTrials.gov 
number, NCT01300481.)
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T
uberculosis is a major cause of death 
in persons infected with the human im-
munodeficiency virus (HIV), especially in 
resource-limited settings.1,2 Despite effective tu-
berculosis therapy, mortality is particularly high 
among patients with severe immunosuppression.3,4 
Although mortality among HIV-infected patients 
has been reported to be approximately 30% within 
the first 2 months of tuberculosis treatment if an-
tiretroviral therapy (ART) is withheld,5 the timing 
for starting ART in patients with tuberculosis has 
remained unclear.
Arguments that support delayed initiation of 
ART include concern about the combined toxic 
effects of drugs, an increased risk of the im-
mune  reconstitution  inflammatory  syndrome 
(IRIS), and poor adherence to a regimen that 
involves an increased pill burden. In contrast, 
arguments that support earlier initiation of ART 
include more rapid restoration of the immuno-
competence needed to cure the tuberculosis and 
the enhancement of immune responses to other 
specific pathogens, thus reducing the risk of op-
portunistic infections.6,7 The Starting Antiretro-
viral  Therapy  at  Three  Points  in  Tuberculosis 
(SAPIT)  study  (ClinicalTrials.gov  number, 
NCT00398996) showed that initiating ART dur-
ing tuberculosis therapy provided a significant 
survival advantage in patients with CD4+ T-cell 
counts  lower  than  500  per  cubic  millimeter.8 
The retrospective Multicenter Cohort of Patients 
with HIV Infection in the Madrid South-Eastern 
Metropolitan Crown (COMESEM) study showed 
that survival was further increased when ART 
was started within 2 months after the start of 
tuberculosis treatment.9 On the basis of these 
data,  the  World  Health  Organization  (WHO) 
guidelines recommend that ART be started as 
soon as possible within the first 8 weeks after 
tuberculosis therapy is begun.10 However, there 
has been no specific guidance regarding tim-
ing  within  this  critical  period,  owing  to  the 
lack of evidence-based research addressing this 
point.
To determine whether the earlier initiation of 
ART (2 weeks after the onset of tuberculosis treat-
ment), as compared with later initiation (8 weeks 
afterward), could reduce mortality among patients 
with advanced immunodeficiency, we designed the 
Cambodian Early versus Late Introduction of Anti-
retrovirals (CAMELIA) trial.
Methods
Study Design and Oversight
CAMELIA was a prospective, randomized, multi-
center, open-label superiority trial (with no place-
bo) designed to determine the effect of earlier 
versus later initiation of ART on mortality among 
HIV-infected adults with no previous exposure to 
antiretroviral drugs who had a CD4+ T-cell count 
of 200 per cubic millimeter or less and had received 
a new diagnosis of tuberculosis, as confirmed by 
any clinical sample that was smear-positive for acid-
fast bacilli.
Inpatients and outpatients were recruited be-
tween January 31, 2006, and May 27, 2009, from 
five hospitals in Cambodia. (For detailed inclusion 
criteria, see the Supplementary Appendix, available 
with the full text of this article at NEJM.org.) 
After providing written informed consent, patients 
were randomly assigned to begin ART either ear-
lier (2 weeks [±4 days]) or later (8 weeks [±4 days]) 
after the start of treatment for tuberculosis. Ran-
domization  was  performed  with  the  use  of  a 
computer-generated, per-block, random-numbers 
list in a 1:1 ratio and was stratified according to 
study site and CD4+ T-cell count at enrollment 
(≤50 or 51 to 200 per cubic millimeter). The study 
was conducted in accordance with the protocol, 
which is available at NEJM.org. The funding agen-
cies had no role in the study design, data collection 
and analysis, or decision to submit the manuscript 
for publication.
The trial was approved by the ethics review 
boards of the Cambodian government, the Im-
mune Disease Institute, and Médecins sans Fron-
tières. Patient representatives and community advi-
sory boards participated in the implementation 
and review of the trial.
Study Intervention
Patients were evaluated by on-site clinicians at 
2, 4, 8, 10, 14, 18, 22, 26, 34, 42, and 50 weeks after 
the initiation of antituberculosis therapy, again at 
weeks 58 and 78, and every 6 months thereafter 
until the end of data collection, which was 50 weeks 
after the last patient was enrolled (May 13, 2010). 
Tuberculosis treatment consisted of a standard dai-
ly regimen of isoniazid, rifampin, ethambutol, and 
pyrazinamide during the first 2 months, followed 
by daily administration of isoniazid and rifampin 
during the ensuing 4 months. Mycobacterial cul-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF LIVERPOOL on April 13, 2012. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. earlier vs. later ART in HIV and tb
n engl j med 365;16  nejm.org  october 20, 2011 1473
ture and drug-susceptibility testing were system-
atically performed at the time of enrollment and 
in the event of treatment failure or recurrence of 
tuberculosis. When drug resistance was document-
ed, tuberculosis treatment was modified on the ba-
sis of the WHO guidelines11 or the results of testing 
for susceptibility to second-line drugs.
All patients received counseling regarding ad-
herence to the treatment regimen, as well as pro-
phylaxis with trimethoprim–sulfamethoxazole and 
fluconazole (if the CD4+ T-cell count was below 
100 per cubic millimeter). ART consisted of stavu-
dine, lamivudine, and efavirenz, in accordance 
with the Cambodian national guidelines. After 
1 year of follow-up, recommendations were given 
to consider switching from stavudine to zidovu-
dine to minimize the risk of mitochondrial toxic 
effects and switching from efavirenz to nevirapine 
to reduce costs in accordance with Cambodian 
national guidelines and to avoid the risk of injury 
to the fetus in case of pregnancy.
Study End Points
The primary study end point was survival. Second-
ary end points included tuberculosis outcome, 
CD4+ T-cell count, viral load below the detection 
threshold (2.4 log10 [250] copies per milliliter), side 
effects of the drugs, and the occurrence of tubercu-
losis-associated IRIS, which was defined as the 
worsening or emergence of tuberculosis symptoms 
661 Were enrolled and underwent randomization
778 HIV-infected adults with positive acid-fast
bacilli for any smear were screened
117 Were excluded
81 Had CD4+ T-cell count >200/mm3
25 Had aminotransferase levels >5× ULN
4 Had positive pregnancy test
2 Had TB treatment started 
>1 wk before randomization
2 Died before randomization
1 Had no CD4+ T-cell count
1 Had bilirubin level >5× ULN
1 Had delayed blood sampling
332 Were assigned to earlier-ART group
(at 2 wk after start of TB treatment)
329 Were assigned to later-ART group
(at 8 wk after start of TB treatment)
104 (32%) Did not complete
 follow-up
90 (27%) Died
6 (2%) Withdrew consent
2 (1%) Were transferred
6 (2%) Were lost to 
follow-up
73 (22%) Did not complete
 follow-up
59 (18%) Died
6 (2%) Withdrew consent
2 (1%) Were transferred
6 (2%) Were lost to 
follow-up
259 (78%) Remained in active
follow-up until end of study
225 (68%) Remained in active
follow-up until end of study
Figure 1. Screening, Enrollment, and Follow-up.
Of the 4 patients who were not enrolled because of a positive pregnancy test, 1 also had impaired liver function.  
Of the 81 patients who were not enrolled because their CD4+ T-cell counts exceeded 200 per cubic millimeter,  
2 also had impaired liver function and 1 was pregnant. ART denotes antiretroviral therapy, TB tuberculosis, and 
ULN upper limit of the normal range.
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after the initiation of ART in any patient who had 
no evidence of newly acquired infection, evolution 
of drug-resistant tuberculosis, infection with a pre-
viously recognized pathogen, or side effects of anti-
retroviral therapy. The adjudication of IRIS was not 
blinded.
HIV Laboratory Monitoring
CD4+ T-cell counts and plasma HIV RNA viral 
loads (Biocentric)12,13 were measured at weeks 
8, 26, 50, and 78 and then every 6 months. Bulk 
sequencing of reverse transcriptase, protease, or 
both was performed to detect resistance mutations 
in all patients with a detectable viral load at week 
50 and thereafter.
Statistical Analysis
On the basis of empirical observations and the 
available literature,14,15 mortality in the reference 
group (i.e., patients receiving ART later, at 8 weeks) 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Earlier ART
(N = 332)
Later ART
(N = 329) P Value
Male sex — no. of patients (%) 215 (64.8) 210 (63.8) 0.80
Age — yr 0.38
Median 35 36
Interquartile range 30–41 30–42
Body-mass index† 0.90
Median 16.7 16.8
Interquartile range 15.3–18.3 15.2–18.6
Karnofsky performance score — no. of patients (%)‡ 0.83
≥80 43 (13.0) 44 (13.4)
50 to 70 259 (78.0) 251 (76.3)
≤40 30 (9.0) 34 (10.3)
CD4+ T-cell count 0.61
Median — per mm3 25 25
Interquartile range — per mm3 11–56 10–55
CD4+ T-cell count level 0.79
≤50/mm3 — no. of patients (%) 237 (71.4) 238 (72.3)
51–200/mm3 — no. of patients (%) 95 (28.6) 91 (27.7)
Viral load — log10 copies/ml 0.25
Median 5.60 5.66
Interquartile range 5.20–6.02 5.25–6.00
Hemoglobin — g/dl 0.98
Median 8.7 8.7
Interquartile range 7.1–10.4 7.0–10.2
Opportunistic infections — no. of patients (%)
Pneumocystis jirovecii pneumonia 3 (0.9) 7 (2.1) 0.22
Esophageal candidiasis 8 (2.4) 6 (1.8) 0.60
Extrapulmonary cryptococcosis 6 (1.8) 4 (1.2) 0.53
Cryptosporidiosis, with diarrhea for >1 mo 1 (0.3) 1.00
Herpes simplex infection 1 (0.3) 1.00
Progressive multifocal leukoencephalopathy 1 (0.3) 1.00
* ART denotes antiretroviral therapy.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ The Karnofsky performance score is a measure of the patient’s general condition and degree of autonomy on a scale 
ranging from 0 to 100, with higher numbers indicating better performance.
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was expected to be 35%. Assuming that mortality 
would be reduced by 10% in the earlier-ART group 
(hazard ratio, 1.5), with a two-sided type I error rate 
of 5%, a power of 80%, and use of a log-rank 
test, we calculated that we would need to enroll 
330 patients in each of the two treatment groups.
A data and safety monitoring board reviewed 
interim analyses that were not shared with the 
study team. The prespecified rule for stopping 
the study was based on the boundary for signifi-
cance, as described by Peto et al.16 and Slutsky and 
Lavery.17 There were six board meetings between 
February 2006 and September 2009, during which 
early termination of the study was not considered. 
On November 7, 2006, the board recommended 
that all patients be followed to the calendar-date 
end of the study (50 weeks after enrollment of the 
last patient) rather than for only 50 weeks, as 
originally  scheduled.  The  study  protocol  was 
amended accordingly.
Analyses were based on the intention-to-treat 
principle. Between-group comparisons of charac-
teristics of the patients were performed with the 
use of Student’s t-test for continuous variables and 
the chi-square test or Fisher’s exact test for categor-
ical variables. The primary end point, survival, was 
described with the use of Kaplan–Meier estimates 
and was compared between groups with the use of 
the log-rank test, as specified in the protocol.18
The Cox proportional-hazards model was used to 
identify factors associated with an increased risk of 
death. Factors associated with mortality with a 
P value of less than 0.20 in the univariate analysis 
were entered in the multivariate model, and non-
significant factors were removed by means of a 
backward-selection procedure. The proportional-
hazards assumption was checked with the use of 
a test on Schoenfeld residuals and was found to be 
valid for all factors investigated. Two-sided hypoth-
eses and tests were used for all statistical infer-
ences. A P value of less than 0.05 was considered 
to indicate statistical significance.
Results
Characteristics of the Patients
A total of 661 patients (236 women) were enrolled 
in the study: 332 in the earlier-ART group and 
329 in the later-ART group (Fig. 1). The median age 
of those enrolled was 35 years, the median body-
mass index (the weight in kilograms divided by the 
square of the height in meters) was 16.7, the medi-
an CD4+ T-cell count was 25 per cubic millimeter, 
and the median viral load was 5.64 log10 copies per 
milliliter. There were no significant differences be-
tween the two groups with regard to baseline char-
acteristics (Table 1).
Positive smears for acid-fast bacilli were ob-
tained from the respiratory tract in 278 of the 
332 patients (83.7%) in the earlier-ART group 
and in 278 of the 329 patients (84.5%) in the 
later-ART  group  (P = 0.25).  (A  list  of  positive 
smears obtained from other anatomical sites can 
be found in the Supplementary Appendix.) Mycobac-
terium tuberculosis was identified by means of culture 
in 282 patients (84.9%) and 295 patients (89.7%) 
in the earlier-ART and later-ART groups, respec-
tively, and nontuberculous mycobacteria were iden-
tified in 12 patients (3.6%) and 4 patients (1.2%) 
in the two groups, respectively. Culture results were 
negative in the remaining 38 patients (11.4%) in 
the earlier-ART group and 30 patients (9.1%) in the 
later-ART group and thus did not permit mycobac-
terial identification. The pattern of distribution 
of tuberculosis-drug resistance was similar in the 
two treatment groups (see the Supplementary 
Appendix).
Follow-up
The median follow-up period was 25 months (inter-
quartile range, 14 to 36). Of the 332 participants 
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Figure 2. Kaplan–Meier Survival Estimates According to Study Group.
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in the earlier-ART group, 259 (78.0%) were fol-
lowed until the end of the study, 59 (17.8%) died, 
6 (1.8%) withdrew, 2 (0.6%) were transferred to 
another facility for follow-up, and 6 (1.8%) were 
lost to follow-up. Of the 329 participants in the 
later-ART group, 225 (68.4%) were followed until 
the end of the study: 90 (27.4%) died, 6 (1.8%) with-
drew, 2 (0.6%) were transferred, and 6 (1.8%) were 
lost to follow-up. The leading cause of death was 
tuberculosis in both groups (see the Supplementary 
Appendix).
Survival
Patients in the earlier-ART group had a significant-
ly higher rate of survival than did those in the 
later-ART group (P = 0.004 by the log-rank test) 
(Fig. 2). The rate of death was 8.28 per 100 person-
years (95% confidence interval [CI], 6.42 to 10.69) 
in the earlier-ART group and 13.77 per 100 person-
years (95% CI, 11.20 to 16.93) in the later-ART 
group (P = 0.002). In the multivariate analysis, the 
adjusted hazard ratio for death in the earlier-ART 
group, as compared with the later-ART group, was 
Table 2. Factors Associated with Mortality.*
Factor
Crude Hazard Ratio  
on Univariate Analysis  
(95% CI) P Value
Adjusted Hazard Ratio 
on Multivariate Analysis 
(95% CI)† P Value
Treatment group 0.004 0.006
Earlier ART 0.62 (0.45–0.86) 0.62 (0.44–0.86)
Later ART 1.00 1.00
Sex 0.05
Male 1.00
Female 1.39 (1.00–1.92)
Age 0.14 0.03
≤29 yr 1.00 1.00
30–39 yr 1.12 (0.72–1.75) 1.26 (0.81–1.98)
≥40 yr 1.50 (0.96–2.33) 1.87 (1.18–2.95)
Body-mass index 0.001 0.02
<16.0 1.79 (1.17–2.75) 1.61 (1.03–2.54)
16.0–17.0 0.86 (0.49–1.51) 0.84 (0.47–1.48)
17.1–18.5 0.93 (0.54–1.60) 1.08 (0.62–1.91)
>18.5 1.00 1.00
Karnofsky performance score <0.001 <0.001
≥80 1.00 1.00
50–70 1.78 (0.95–3.30) 1.60 (0.83–3.09)
≤40 5.23 (2.62–10.43) 4.69 (2.17–10.11)
CD4+ T-cell count 0.01 0.24
≤50 per mm3 1.60 (1.08–2.38) 1.29 (0.84–1.98)
51–200 per mm3 1.00 1.00
Viral load 0.80
≤5.0 log10 copies/ml 1.00
5.1–6.0 log10 copies/ml 1.15 (0.73–1.80)
>6.0 log10 copies/ml 1.05 (0.62–1.76)
Hemoglobin level <0.001
≤7.0 g/dl 2.53 (1.59–4.01)
7.1–8.5 g/dl 1.65 (1.00–2.73)
8.6–10.0 g/dl 1.73 (1.06–2.83)
>10.0 g/dl 1.00
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0.62 (95% CI, 0.44 to 0.86; P = 0.006). Even when 
patients who were lost to follow-up were considered 
to have died, survival remained significantly high-
er in the earlier-ART group (P = 0.005).
In the multivariate analysis, factors at study in-
clusion other than the later start of ART that were 
independently associated with an increased risk of 
death were an age of 40 years or older, a body-mass 
index less than 16, a Karnofsky performance score 
below 40 (on a scale that ranges from 0 to 100, 
with higher scores indicating better performance), 
an aspartate aminotransferase level more than 
1.25 times the upper limit of the normal range, 
disseminated tuberculosis, nontuberculous my-
cobacterial disease, and multidrug-resistant tu-
berculosis (i.e., tuberculosis that was resistant 
to isoniazid and rifampin) (Table 2). When the 
13 patients with multidrug-resistant tuberculo-
sis or the 16 patients with nontuberculous myco-
bacterial disease were excluded, the adjusted haz-
ard ratios for death in the earlier-ART group, as 
compared with the later-ART group, were 0.63 
(95% CI, 0.45 to 0.88) and 0.60 (95% CI, 0.43 to 
0.85), respectively. In the multivariate analysis, a 
CD4+ T-cell count of 50 per cubic millimeter or 
lower at study entry was not associated with an 
increased risk of death, as compared with a count 
of 51 to 200 per cubic millimeter (P = 0.24). To test 
whether the effect of initiating ART early would be 
similar between patients with lower CD4+ T-cell 
counts and those with higher counts, we intro-
duced an interaction between the CD4+ T-cell 
count category (≤50 per cubic millimeter vs. 51 to 
200 per cubic millimeter) and the study group: 
the hazard ratio associated with earlier ART did 
not  differ  significantly  between  patients  with 
Table 2. (Continued.)
Factor
Crude Hazard Ratio
on Univariate Analysis 
(95% CI) P Value
Adjusted Hazard Ratio 
on Multivariate Analysis 
(95% CI)† P Value
Aspartate aminotransferase level <0.001 0.02
≤1.25× ULN 1.00 1.00
>1.25× ULN 1.76 (1.26–2.48) 1.53 (1.08–2.18)
Alanine aminotransferase level 0.84
≤1.25× ULN 1.00
>1.25× ULN 0.95 (0.61–1.50)
Mycobacterial disease pattern <0.001 <0.001
Pulmonary tuberculosis 1.00 1.00
Extrapulmonary tuberculosis 0.99 (0.51–1.91) 1.02 (0.52–2.01)
Disseminated tuberculosis 2.52 (1.78–3.55) 2.55 (1.78–3.65)
Nontuberculous mycobacteria 3.00 (1.30–6.88) 3.21 (1.35–7.63)
Tuberculosis-drug resistance 0.01 <0.001
No 1.00 1.00
Yes 0.95 (0.60–1.50) 1.10 (0.68–1.74)
Multidrug resistance‡ 3.60 (1.76–7.39) 7.65 (3.45–16.99)
Tuberculosis-associated IRIS§ 0.37
No 1.00
Yes 0.83 (0.51–1.30)
Hospitalization 0.85
No 1.00
Yes 0.97 (0.70–1.34)
* All factors except immune reconstitution   inflammatory syndrome (IRIS) were present at study inclusion. Values were 
calculated with the use of Cox univariate and multivariate models. ULN deneotes upper limit of the normal range.
† Values were adjusted according to two stratification factors: study site and CD4+ T-cell count at baseline.
‡ Multidrug resistance was defined as resistance to both isoniazid and rifampin.
§ This factor was time-dependent, since exposure to the risk was considered to extend until week 50.
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lower  counts  and  those  with  higher  counts 
(P = 0.49).
Tuberculosis Outcomes
The median duration of tuberculosis treatment 
was 26.0 weeks (interquartile range, 25.8 to 26.9) 
in the earlier-ART group and 26.0 weeks (inter-
quartile range, 25.7 to 26.4) in the later-ART group 
(P  =  0.13). When tuberculosis treatment ended, there 
was no significant difference between the two 
groups  with  regard  to  tuberculosis  outcomes 
(see the Supplementary Appendix). Recurrence 
of tuberculosis was observed in 22 patients: 8 in 
the earlier-ART group and 14 in the later-ART 
group (P = 0.11).
Virologic Response and Immune 
Reconstitution
ART was initiated in 319 of 332 patients (96%) in 
the earlier-ART group at a median of 14 days after 
the onset of tuberculosis treatment (interquartile 
range, 14 to 15) and in 300 of 329 patients (91%) in 
the later-ART group at a median time of 56 days 
(interquartile range, 56 to 57). At week 50, the 
viral load was undetectable in 96.5% of patients, 
with no difference between the two study groups 
(P = 0.82), whereas the median gain in the CD4+ 
T-cell count was 118 per cubic millimeter (inter-
quartile range, 67 to 191) in the earlier-ART group 
and 112 per cubic millimeter (interquartile range, 
53 to 175) in the later-ART group (P = 0.22). At all 
subsequent follow-up times, there was no differ-
ence between the groups in the percentage of pa-
tients with an undetectable viral load (which re-
mained consistently above 95%) or in the median 
CD4+ T-cell count (Fig. 3).
Tuberculosis-Associated IRIS
The incidence of tuberculosis-associated IRIS with-
in the first 50 weeks of follow-up was 3.76 cases 
per 100 person-months (95% CI, 3.14 to 4.47) in the 
earlier-ART group and 1.53 cases per 100 person-
months (95% CI, 1.13 to 2.03) in the later-ART 
group. Thus, the risk of tuberculosis-associated 
IRIS was significantly increased in the earlier-ART 
group, with 110 events, as compared with 45 events 
in the later-ART group (hazard ratio, 2.51; 95% CI, 
1.78 to 3.59; P<0.001). After the initiation of ART, 
tuberculosis-associated IRIS occurred at a medi-
an of 14 days (interquartile range, 10 to 42) in the 
earlier-ART group and 16 days (interquartile range, 
11 to 39) in the later-ART group (P = 0.89). Six 
deaths were directly related to tuberculosis-associ-
ated IRIS, all occurring in the earlier-ART group.
Adverse Events
The incidence of serious drug-related adverse events 
was 2.93 events per 100 person-months (95% CI, 
2.58 to 3.32) in the earlier-ART group and 3.21 
(95% CI, 2.83 to 3.63) in the later-ART group 
(P = 0.31). Hepatic toxic effects accounted for 43% 
of all serious drug-related adverse events (Table 3). 
Drug toxicity was the second most common cause 
of death, after tuberculosis, accounting for 5 and 
12 deaths (including 4 and 6 due to lactic acidosis) 
in the earlier-ART and later-ART groups, respec-
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Figure 3. Changes in the CD4+ T-Cell Count and Percentage of Patients 
with Undetectable Viral Load during Follow-up.
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tively. (Additional information about adverse events 
can be found in the Supplementary Appendix.)
Discussion
The results of the CAMELIA trial show that initi-
ating ART 2 weeks after the start of tuberculosis 
therapy significantly increases survival among HIV-
infected adults with newly diagnosed tuberculosis 
and CD4+ T-cell counts of 200 per cubic millimeter 
or lower, as compared with delaying the start of 
ART for 8 weeks. The benefit of earlier ART was 
observed in patients with CD4+ T-cell counts of 
50 per cubic millimeter or lower, as well as in pa-
tients with counts between 51 and 200 per cubic 
millimeter. For such patients, these results argue 
strongly in favor of beginning ART earlier despite 
an increased risk of IRIS. This is of particular 
relevance in resource-limited settings where tuber-
culosis is the leading cause of death in HIV-infected 
patients.19-21
Two other studies that examined the timing of 
ART in patients coinfected with tuberculosis are 
reported by Havlir et al.22 and by Abdool Karim 
et al.23 in this issue of the Journal. These studies 
differ from ours with respect to their design and 
the characteristics of their patient populations (i.e., 
higher body-mass index22 and higher baseline 
CD4+ T-cell counts22,23), which may at least in part 
explain the markedly lower overall mortality ob-
served in these two studies (6.6% and 7.0%, re-
spectively), as compared with an overall mortal-
ity in our study of more than 16% at week 50. 
The combination of applying our investigational 
strategy to this patient population, together with 
the  longer  follow-up  period,  maximized  our 
ability to observe a potential survival difference 
between the earlier and later start of ART.
We chose to enroll patients with a positive 
smear for acid-fast bacilli in order to confirm the 
diagnosis of tuberculosis. Given the high level of 
immunodeficiency in all the patients enrolled and 
the focus on detection of acid-fast bacilli in this 
trial, we believe that our results would have been 
similar in similarly immunocompromised patients 
with negative smears. This view is supported by an 
observational study that showed no difference 
in mortality between HIV-infected patients with 
smear-positive and smear-negative pulmonary tu-
berculosis or extrapulmonary tuberculosis.24
Initiation of ART early in the course of tuber-
culosis treatment is associated with an increased 
incidence of tuberculosis-associated IRIS, espe-
cially when the CD4+ T-cell count is 50 per cubic 
millimeter or lower.25,26 We found that even though 
the incidence of IRIS was increased by a factor of 
2.5 in the earlier-ART group, as compared with the 
later-ART group, and six cases were fatal, the sur-
vival rate was still higher in the earlier-ART group. 
Most cases of IRIS developed 2 to 3 weeks after the 
initiation of ART, irrespective of the study group. 
Thus, within the first weeks after ART is begun, 
clinicians must anticipate the possible occurrence 
of IRIS, which may require aggressive manage-
ment.27,28 Studies of the mechanisms underlying 
the development of IRIS are under way, with a fo-
cus on natural killer cells and T cells.
In CAMELIA, the efficacy of ART was excel-
lent,  irrespective  of  the  treatment  group,  as 
evidenced by a median gain in the CD4+ T-cell 
count that exceeded 100 per cubic millimeter and 
an undetectable viral load at week 50 in more 
than 95% of patients, which remained undetect-
able until the end of the trial. Nesting the trial 
in established clinical networks devoted to deliv-
ery of care and support of patient adherence to 
Table 3. Distribution of Serious Drug-Related Adverse Events.*
Event Earlier ART Later ART Total
number of events
Hepatic toxicity 107 105 212
Anemia 69 43 112
Mitochondrial toxicity 16 19 35
Cutaneous toxicity 10 22 32
Electrolyte disorders 12 14 26
Metabolic disorders 11 10 21
Neutropenia 7 14 21
Peripheral neuropathy 8 8 16
Gastrointestinal disorders 3 6 9
Neuropsychiatric disorders 6 1 7
Ocular toxicity 1 2 3
Hypothyroidism 0 1 1
Ototoxicity 1 0 1
Total 251 245 496
* Serious adverse events were defined as those that were grade 3 or higher. 
Drugs included antiretroviral agents.
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treatment certainly contributed to this achievement 
by maintaining a low rate of loss to follow-up.29-32
The goal of shortening the time to the start of 
ART was to significantly reduce the time that pa-
tients had profound immunodeficiency, since in-
creased mortality among patients with the ac-
quired immunodeficiency syndrome is strongly 
associated with the length of time that the CD4+ 
T-cell count is below 200 per cubic millimeter, 
particularly when the count remains below 50 per 
cubic millimeter.33
The  median  duration  of  follow-up  was  25 
months, which allowed us to assess whether the 
reduction in mortality observed in the earlier-ART 
group was maintained for longer than 12 months 
after the beginning of the study. The survival ben-
efit derived from starting ART early continued to 
be observed up to 3 years. This survival advantage 
cannot be attributed to a difference between the 
two treatment groups with respect to the virologic 
response or the gain in the CD4+ T-cell count. 
Although the survival advantage was presumably 
related to the earlier immune reconstitution that 
occurred in the earlier-ART group, the precise un-
derlying mechanism remains to be determined.
In summary, the CAMELIA trial showed a sig-
nificant survival benefit when ART was initiated 
2 weeks after the start of tuberculosis treatment in 
HIV-infected patients with a CD4+ T-cell count of 
200 per cubic millimeter or lower.
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